07Jan 2023
Trial of Intravenous Immune Globulin in Dermatomyositis

Trial of Intravenous Immune Globulin in Dermatomyositis

The placebo-controlled, phase 3 trial of intravenous immune globulin (IVIG) in patients with dermatomyositis that was conducted by Aggarwal et al. (Oct. 6 issue) represents an important advance. It is unfortunate that the trial excluded patients with the skin-predominant disease, including those with a muscle disease that had resolved. This group comprised more than 20% of patients in a population-based study. In the trial, it is clear that IVIG treatment was effective for skin disease, given the clinically significant improvement observed in the score on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI).

  • #family health

Like

Save

Share